Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
LXRX
LXRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LXRX News
Lexicon Pharmaceuticals Q4 2025 Earnings Call Insights
4d ago
seekingalpha
Lexicon Pharmaceuticals Q4 Earnings Beat Expectations
5d ago
seekingalpha
Lexicon Pharmaceuticals to Announce Q4 Earnings on March 5
6d ago
seekingalpha
Chronic Kidney Disease Market Growth Drivers
6d ago
Newsfilter
Lexicon Pharmaceuticals Chairman Buys Over $350K in Shares
Feb 19 2026
seekingalpha
Lexicon Pharmaceuticals Closes 32 Million Share Public Offering
Feb 06 2026
Newsfilter
Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share
Jan 30 2026
seekingalpha
Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share
Jan 30 2026
Newsfilter
Lexicon Pharmaceuticals Launches Underwritten Public Offering
Jan 29 2026
seekingalpha
Lexicon Pharmaceuticals Launches Underwritten Public Offering
Jan 29 2026
Newsfilter
Lexicon Pharmaceuticals (LXRX) Advances Pilavapadin to Phase 3 Following Positive FDA Meeting
Jan 21 2026
seekingalpha
Lexicon Pharmaceuticals (LXRX) Advances Pilavapadin to Phase 3 After FDA Approval
Jan 21 2026
NASDAQ.COM
Progress Software Corp Reports Q4 EPS Beat, Shares Surge 20.5%
Jan 21 2026
Benzinga
Lexicon Pharmaceuticals Completes FDA End-of-Phase 2 Meeting, Advancing DPNP Drug Development
Jan 21 2026
Globenewswire
Lexicon Pharmaceuticals' SONATA-HCM Study on Track for 2026 Enrollment Completion
Jan 12 2026
seekingalpha
Lexicon Pharmaceuticals Triggers $10 Million Milestone Payment with Novo Nordisk for LX9851
Jan 12 2026
Globenewswire
Show More News
